GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EOM Pharmaceutical Holdings Inc (OTCPK:IMUC) » Definitions » Cash Flow from Investing

EOM Pharmaceutical Holdings (EOM Pharmaceutical Holdings) Cash Flow from Investing : $0.00 Mil (TTM As of Jun. 2018)


View and export this data going back to 2006. Start your Free Trial

What is EOM Pharmaceutical Holdings Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Jun. 2018, EOM Pharmaceutical Holdings spent $0.00 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $0.00 Mil on purchasing investments. It gained $0.00 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, EOM Pharmaceutical Holdings gained $0.00 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Jun. 2018.


EOM Pharmaceutical Holdings Cash Flow from Investing Historical Data

The historical data trend for EOM Pharmaceutical Holdings's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EOM Pharmaceutical Holdings Cash Flow from Investing Chart

EOM Pharmaceutical Holdings Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.04 -0.03 -0.17 - -

EOM Pharmaceutical Holdings Quarterly Data
Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

EOM Pharmaceutical Holdings Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

EOM Pharmaceutical Holdings's Cash Flow from Investing for the fiscal year that ended in Dec. 2017 is calculated as:

EOM Pharmaceutical Holdings's Cash Flow from Investing for the quarter that ended in Jun. 2018 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Jun. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


EOM Pharmaceutical Holdings  (OTCPK:IMUC) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

EOM Pharmaceutical Holdings's purchase of property, plant, equipment for the three months ended in Jun. 2018 was $0.00 Mil. It means EOM Pharmaceutical Holdings spent $0.00 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

EOM Pharmaceutical Holdings's sale of property, plant, equipment for the three months ended in Jun. 2018 was $0.00 Mil. It means EOM Pharmaceutical Holdings gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

EOM Pharmaceutical Holdings's purchase of business for the three months ended in Jun. 2018 was $0.00 Mil. It means EOM Pharmaceutical Holdings spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

EOM Pharmaceutical Holdings's sale of business for the three months ended in Jun. 2018 was $0.00 Mil. It means EOM Pharmaceutical Holdings gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

EOM Pharmaceutical Holdings's purchase of investment for the three months ended in Jun. 2018 was $0.00 Mil. It means EOM Pharmaceutical Holdings spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

EOM Pharmaceutical Holdings's sale of investment for the three months ended in Jun. 2018 was $0.00 Mil. It means EOM Pharmaceutical Holdings gained $0.00 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

EOM Pharmaceutical Holdings's net Intangibles purchase and sale for the three months ended in Jun. 2018 was $0.00 Mil. It means EOM Pharmaceutical Holdings paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

EOM Pharmaceutical Holdings's cash from discontinued investing activities for the three months ended in Jun. 2018 was 0.00 Mil. It means EOM Pharmaceutical Holdings paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

EOM Pharmaceutical Holdings's cash from other investing activities for the three months ended in Jun. 2018 was $0.00 Mil. It means EOM Pharmaceutical Holdings paid $0.00 Mil for other investing activities.


EOM Pharmaceutical Holdings Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of EOM Pharmaceutical Holdings's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


EOM Pharmaceutical Holdings (EOM Pharmaceutical Holdings) Business Description

Traded in Other Exchanges
N/A
Address
136 Summit Avenue, Suite 100, Montvale, NJ, USA, 07645
EOM Pharmaceutical Holdings Inc is focused on developing novel immunomodulatory and retinal disease drug agents to address a range of inflammatory, viral, retinal, and other diseases. Its product candidate includes dual-acting broad-spectrum immunomodulator EOM613, which has the potential to treat cancer cachexia and rheumatoid arthritis, and its advanced formulation of EOM147 is being studied to treat serious retinal diseases without the need for intraocular injection.
Executives
Andrew Gengos director 21900 BURBANK BOULEVARD, 3RD FLOOR, WOODLAND HILLS CA 91367
Gary Titus director, officer: Chairman and Secretary SCICLONE PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404-2125
Anthony Gregg Lapointe director PO BOX 83216, GAITHERSBURG MD 20883-3216
Mark A Schlossberg director C/O IMPAX LABORATORIES, INC., 30831 HUNTWOOD AVENUE, HAYWARD CA 94544
Rahul Singhvi director 246 HOLLY DRIVE, CHALFONT PA 18914
Helen Susan Kim director 3832 BAY CENTER PLACE, HAYWARD CA 94545
Richard Chin director C/O OXIGENE, INC., 230 THIRD AVENUE, WALTHAM MA 02451
Richard Cowell director 7840 VIRGINIA OAK DRIVE, GAINSVILLE VA 20155
James G. Bender officer: VP, Product Development & Mfg. 112 WEST 34TH STREET, 17TH FLOOR, NEW YORK NY 10120
Manish Singh director, officer: President & CEO 21900 BURBANK BOULEVARD, 3RD FLOOR, WOODLAND HILLS CA 91367
Jacqueline Brandwynne director 649 STONE CANYON ROAD, LOS ANGELES CA 90077